Lurbinectedin Shows Modest Efficacy and Safety in ES-SCLC
In a multicentre study, lurbinectedin demonstrated a favourable safety profile and consistent efficacy and may be considered for compassionate use in patients with extensive-stage small cell lung cancer (ES-SCLC). However, poor performance status, a chemotherapy-free interval of less than 90 days, and the presence of brain or liver metastases may have negatively affected overall survival (OS).
METHODOLOGY:
This multicentric, international cohort included 238 adult patients with ES-SCLC (median age, 65 years) who received lurbinectedin intravenously at 3.2 mg/m 2 every 3 weeks as second- or further-line treatment between November 2019 and September 2024.
every 3 weeks as second- or further-line treatment between November 2019 and September 2024. The primary objective was to assess the effectiveness of lurbinectedin with regard to objective response rate, disease control rate, duration of response, progression-free survival (PFS), and OS and its safety profile.
The median follow-up duration was 5.53 months.
TAKEAWAY:
Overall, 37% of patients received lurbinectedin as second-line therapy, 45% received it as third-line therapy, and 18% received it as further-line therapy. The objective response rate was 23.1%, and the disease control rate was 45.4%.
The median PFS was 2.2 months, and the median OS was 5.4 months. The 6-month PFS and OS rates were 12.2% and 42.4%, respectively.
Patients with a chemotherapy-free interval of 90 days or more showed significantly longer PFS (3.1 vs 1.8 months; hazard ratio [HR], 0.46; P < .001) and OS (6.8 vs 4.5 months; HR, 0.56; P = .006) than chemoresistant patients.
Eastern Cooperative Oncology Group performance status of two or more at treatment start and the presence of brain or liver metastases were associated with worse outcomes.
Treatment-related adverse events (AEs) of any grade were recorded in 92% of patients, with 29% of patients experiencing at least one grade 3-4 toxicity and the most frequent being neutropenia that occurred in 22% of patients.
IN PRACTICE:
"Our study provides valuable real-world insights into the effectiveness and safety of lurbinectedin as compassionate use treatment for ES-SCLC, supporting its use with outcomes consistent with those observed in clinical trials and other real-world studies. However, the outcomes for patients with poor PS [performance status] at lurbinectedin start, a CFI [chemotherapy-free interval] of less than 90 days, and brain or liver metastases remain suboptimal and this should be carefully considered when making treatment decisions," the authors of the study wrote.
SOURCE:
This study was led by Daniela Scattolin, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy. It was published online on July 02, 2025, in the European Journal of Cancer.
LIMITATIONS:
This study was limited by its retrospective design, the small number of participating centres, and imbalanced cohort sizes between countries. Researchers noted heterogeneity in baseline patient characteristics, treatment management strategies, and tumour assessment protocols. Additionally, differences in national regulations regarding chemoimmunotherapy use could have introduced bias. The retrospective nature of data collection may have resulted in underreporting of AEs.
DISCLOSURES:
This study did not receive any specific funding. Several authors reported receiving speaker/consultant fees and having other ties with various sources. Additional disclosures are noted in the original article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
2 hours ago
- Medscape
FDA Approves Drug for Aggressive Glioma
The FDA has granted accelerated approval to dordaviprone (Modeyso, Jazz Pharmaceuticals) for H3 K27M-mutant diffuse glioma, marking the first time a systemic therapy has been approved for the aggressive glioma subtype. H3 K27M-mutant diffuse glioma is a grade 4 midline tumor that primarily affects children and young adults. Median survival is about a year. Historically, treatment has been limited to radiation, with few options available after recurrence besides palliative care. Dordaviprone is a first-in-class oral imipridone that disrupts tumor cell metabolism and increases tumor susceptibility to immune-mediated attack. Jazz Pharmaceuticals bought Chimerix in early 2025 for almost $1 billion based on dordaviprone's commercial prospects. 'Dordaviprone has the potential to rapidly become a standard of care for a rare oncology disease and also contribute durable revenue beginning in the near-term,' Jazz CEO Bruce Cozadd, said in a press release at the time. Approval was based on a pooled analysis of five single-arm studies enrolling 46 adults and four children with recurrent tumors previously treated with radiation, according to a statement from the FDA. Adults received 625 mg once weekly while pediatric patients received lower, weight-adjusted weekly doses. Mutation status was confirmed by immunohistochemistry or sequencing of archival tumor tissue. The overall response rate was 22%. The median time to response was 8.3 months, and the median duration of response (DOR) was 10.3 months. Among 11 patients with objective responses, 73% had a DOR of at least 6 months, and 27% had a DOR of at least 12 months. Seven of 15 evaluable patients (46.7%) were able to have corticosteroid dose reductions of at least 50%, and performance status improved in six of 34 (20.6%) patients. Sixty percent of subjects experienced treatment-related, treatment-emergent adverse events (TR-TEAEs), including fatigue (34%), nausea (18%), decreased lymphocyte levels (14%). The most common serious adverse events were hydrocephalus (8%) and nausea (8%). Grade 3 TR-TEAEs occurred in 20%, most commonly fatigue (10%). One case each of seizure and pulmonary embolism were seen. There were no treatment-related deaths. The drug's prescribing information includes warnings and precautions for hypersensitivity, QTc interval prolongation, and embryo-fetal toxicity, according to the FDA statement. A phase 3 trial is underway to confirm the benefit of dordaviprone for recurrent H3 K27M-mutant diffuse glioma. M. Alexander Otto is a physician assistant with a master's degree in medical science and a journalism degree from Newhouse. He is an award-winning medical journalist who worked for several major news outlets before joining Medscape. Alex is also an MIT Knight Science Journalism fellow. Email: aotto@
Yahoo
4 hours ago
- Yahoo
Eating fries over boiled potatoes increases type 2 diabetes risk
People who eat three portions of French fries a week have a higher risk of developing type 2 diabetes, a new study suggests. Those who consume similar amounts of boiled, baked or mash potatoes do not have an increased risk, researchers found. An international team of researchers, including an expert from the University of Cambridge, wanted to investigate any links between potato consumption and the risk of type 2 diabetes. Academics analysed data on studies tracking the health of more than 205,000 health workers in the US. Repeated surveys about people's diets were performed over almost four decades. And during the study follow-up periods, some 22,000 cases of type 2 diabetes were documented. Overall the research team found that consumption of baked, boiled or mashed potatoes were not linked to an increased risk of type 2 diabetes (T2D). But people who had a higher consumption of French fries – at least three weekly servings – had a 20% increased risk. And those who eat fries five times a week appeared to have a 27% increased risk. 'The risks associated with potato intake varied by cooking method,' the authors wrote in The BMJ. 'The association between higher potato intake and increased T2D risk is primarily driven by intake of French fries. 'Higher intake of French fries, but not combined baked, boiled, or mashed potatoes, was associated with a higher risk of T2D.' The research team also found that replacing three servings of potatoes each week with whole grains was found to lower the risk of type 2 diabetes by 8%. 'Replacing any form of potatoes, particularly French fries, with whole grains is estimated to lower the risk of T2D, reinforcing the importance of promoting whole grains as an essential part of a healthy diet,' they wrote. But replacing potatoes with white rice was associated with an increased risk of type 2 diabetes, they found. The research team also performed a review of all of the other studies on the topic which had similar findings. In a linked editorial, also published in The BMJ, experts from the US and Denmark wrote: 'This finding also corresponds to the observed associations between high intake of ultra-processed foods and high risk of type 2 diabetes – French fries are often ultra-processed, whereas baked, boiled, or mashed potatoes are often minimally processed.' They added: 'With their relatively low environmental impact and their health impact, potatoes can be part of a healthy and sustainable diet, though whole grains should remain a priority.' Commenting on the study, Dr Faye Riley, research communications lead at Diabetes UK, said: 'This research shows that the link between potatoes and type 2 diabetes isn't as clear-cut as it might seem. 'Type 2 diabetes is a complex condition, with many factors influencing its development, including genetics, age and ethnicity. 'Diet is just one part of the picture, but this study suggests that how food is prepared can make a difference and reinforces the advice to prioritise whole grains and cut back on fried or heavily processed foods as a way to support a balanced diet and reduce your risk.'
Yahoo
5 hours ago
- Yahoo
Patients whose lives were ruined after being ‘needlessly given cancer drug for years' sue NHS trust
More than 20 patients who say their quality of life was wrecked when they were needlessly given a highly toxic cancer drug are suing the NHS trust involved. Some people were prescribed temozolomide – which should normally be used for only six months – for more than a decade during treatment by the University Hospitals Coventry and Warwickshire NHS Trust. They say the overprescribing left them with side-effects including secondary cancers and crippling fatigue. Earlier this year the Care Quality Commission was looking into at least 14 cases, but lawyers say more are emerging all the time. An investigation by lawyers Brabners found that, over the past two decades, numerous patients with brain and spinal tumours under the care of Professor Ian Brown were routinely exposed to prolonged and in some cases 'unnecessary' use of the chemotherapy drug, which has severe side-effects including extreme fatigue, confusion, sickness and seizures. The time periods temozolomide was given for allegedly ran contrary to medical and scientific guidelines. Standard NHS procedure is to use the drug over six months, and the drug manufacturer advises it be used for up to 12 months. One man said he was prescribed it for nearly two years longer than necessary, suffering extreme fatigue and low mood as a result. A woman in her twenties said she was misdiagnosed with cancer, receiving the drug needlessly for about eight years. Some patients are now having treatment for secondary cancers allegedly linked to overuse of temozolomide, the lawyers claim. Others claimed its prolonged use left them unable to pursue career ambitions and normal day-to-day activities because the chemotherapy was debilitating, with a long recovery time. Some reported loss of fertility or abnormal blood test results. The legal team says data shows that the trust's spending on the drug of £3.6m from 2009 to 2024 is 10 times that of other NHS oncology departments. The lawyers are now calling for an extended patient safety review and independent investigation, focusing in particular on treatment received by patients under Prof Brown dating back to 2006. The trust has been conducting an internal patient safety review, covering 2017 to 2023, when Prof Brown retired. A patient who identified only as Michael received an extra 22 cycles of temozolomide at the trust, despite his scans being stable. Prof Brown was not present during consultations, and Michael said he was always seen by a clinical nurse specialist. After suffering extreme fatigue and low mood, he learnt through news reports of mistreatment –not from the trust – that he should not have remained on treatment for so long, according to his lawyers. Another patient, identified only as Becky, says she received at least 100 cycles of the drug unnecessarily after being misdiagnosed with a brain tumour. Fiona Tinsley, head of medical negligence at Brabners, said: 'The extent of this scandal, and the physical and mental impact it has had on Prof Brown's patients cannot be underestimated.' She added: 'We believe there are many more patients out there who haven't yet come forward and some who may have sadly passed away. 'While we welcome the ongoing investigations being undertaken by the General Medical Council and Royal College of Physicians, we believe a full independent inquiry is necessary – including an extension of the trust's own review back to 2006 – not only to ensure justice for victims, but that processes are put in place to better identify and prevent such failings happening again.' A spokesperson for the trust told The Independent: 'We have comprehensively reviewed and spoken to all individuals who were receiving temozolomide (TMZ) treatment at the end of 2023 to ensure appropriate support and care plans are in place. 'A glioblastoma is an aggressive brain tumour with fewer than two per cent of patients surviving longer than 10 years. This is an extremely complex condition and all modes of treatment – surgery, chemotherapy and radiotherapy – carry the risk of complications and side-effects. 'National Institute for Health and Care Excellence (Nice) guidelines recognise that clinicians can exercise professional judgment appropriate to individual circumstances when offering treatment to patients. 'We have commissioned the Royal College of Physicians to conduct an independent review of a representative cohort of patients who received greater than 12 cycles of adjuvant TMZ between 2017 and 2023. 'As this process is ongoing, it would be inappropriate to comment further at this stage." It's understood that CQC inspectors have been in touch with the trust to understand the details, and seek assurances that patients are not at risk. The regulator will be reviewing more information to judge whether it needs to be involved. Solve the daily Crossword
